Archive — US — techcrunch
NIH funding uncertainty spurs new biotech venture fund
In response to NIH funding uncertainties, Recursion's CEO Chris Gibson and entrepreneur David Bearss launched the AltitudeLab Pre-seed Venture Fund, aiming to invest $100,000 to $250,000 in early biotech startups impacted by potential delays in government grants, specifically targeting those qualified for SBIR grants.
Key points
- NIH imposed funding limits due to Trump administration directives, affecting biotech startups.
- Federal judge temporarily blocked the NIH policy change but funding delays remain possible.
- Chris Gibson and David Bearss established AltitudeLab Pre-seed Venture Fund to support early biotech companies.
- The fund plans to invest $100,000 to $250,000 in 10-15 startups.
- Gibson emphasized the importance of SBIR grants for biotech success, referencing Recursion's own funding history.
- The fund will provide office and lab space for startups to enhance their growth in the Salt Lake City area.
Why it matters
- The uncertainty in NIH funding mirrors trends influencing biotech investment strategies amidst regulatory changes.
- Similar to past economic shifts, biotech sectors have experienced interruptions in public funding that lead to strategic pivots.
- 2025 IT trends highlight increased investment in AI for drug discovery, driving future biotech innovation.
The establishment of the AltitudeLab Pre-seed Venture Fund exemplifies how biotech entrepreneurs are adapting to funding uncertainties, positioning themselves for growth amidst a challenging financial landscape.